Aim: Sleep disorders are common in Alzheimer's disease (AD) and assumed to directly influence cognitive function and disease progression. This study evaluated sleep characteristics in a rat model of AD that was induced by intracerebroventricular streptozotocin (STZ) administration and assessed the possible underlying mechanisms.
| INTRODUC TI ON
Sleep disturbances are common in Alzheimer's disease (AD). Recent findings in humans support the concept that sleep disturbances are a consequence of disease progression in AD and might also precede symptom onset and drive disease pathology. 1, 2 Improving sleep quality and circadian timing can have immediate positive effects on the quality of life of AD patients and their caregivers, and optimizing these parameters earlier in life might also provide a means of preventing or delaying the development of AD. 3 Understanding the mechanisms by which sleep and circadian disturbances influence the progression of AD may reveal therapeutic targets that are engaged in healthy middle-aged individuals. Sleep and circadian function may thus represent modifiable risk factors for the development of AD that are both diagnostically and therapeutically accessible. Therefore, research is needed to elucidate the role of sleep in the genesis of AD in humans and evaluate sleep parameters as therapeutic and diagnostic targets in AD.
Animals are a useful model to explore the mechanisms of sleep disorders in AD. However, existing evidence of the association between sleep disorders and the pathophysiology of AD in animal studies has been restricted to investigations of transgenic animals.
Transgenic animals have been produced to overexpress mutations that are associated with familial AD (fAD), such as amyloid precursor protein (APP), presenilin 1 (PS1), and PS2. 4 However, the development of sleep disorders in sporadic AD (sAD) is still poorly understood because of a lack of suitable animal models. Epidemiologically, >95% of AD cases are sAD. 5 Therefore, further studies are needed to understand the etiopathogenesis of sleep disorders in sAD.
The intracerebroventricular (i.c.v.) administration of streptozotocin (STZ) at a subdiabetogenic dose in rats and mice is regarded as a credible method to trigger sAD and produce behavioral, neurochemical, and histological features that resemble those that are found in sAD in humans. 6, 7 It is characterized by cognitive impairment, cholinergic deficits, glial activation, neuronal loss, amyloid angiopathy, and other AD-like alterations in the brain. 8, 9 Thus, i.c.v. STZ administration might be a useful model for studying the mechanisms of AD and drug screening. If such a model causes sleep disorders that are similar to those in sAD patients, then this may be helpful for further understanding the associations between cognitive deficits and sleep disorders in sAD. However, to our knowledge, no studies have reported sleep features that are associated with this model. Therefore, this study evaluated sleep characteristics in rats that were given i.c.v.
STZ, and we sought to identify the potential mechanisms that are related to sleep alterations in this model.
| MATERIAL S AND ME THODS

| Animals
A total of 200 male Wistar rats (280-300 g, Grade I, purchased from the Animal Center of Peking University, Beijing, China) were used in this study. The rats were individually housed in plastic cages under an artificial 12-hour/12-hour light/dark cycle (lights on 9:00 am to 9:00 pm)
in a temperature-controlled room (23 ± 1°C, 50%-60% humidity).
Zeitgeber time 0 (ZT 0) and ZT 12 corresponded to lights on (9:00 am) and lights off (9:00 pm), respectively. 10 Subsequently, the cannulas and EEG electrodes were fixed to the skull with dental cement, anchored by three stainless-steel screws. Two stainless-steel wire electrodes were placed in the neck muscles for EMG recordings. During the phase of recovery from surgery, the animals were kept on a heating pad where they were monitored for irregularities in respiration, postoperative pain, and the ability to return to sternal recumbence. After surgery, the rats were injected with penicillin for 3 days and allowed to recover for 7 days prior to the experiments.
| Intracerebroventricular streptozotocin injection
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| Quantification of arousal states
| Morris water maze
The Morris water maze (MWM) test began at 9:00 am, immediately after sleep monitoring, from day 15 after the STZ injection (n = 8-10).
The apparatus consisted of a 185-cm-diameter cylindrical tank filled with water (26 ± 1°C), which was opaque by black nontoxic paint, and a 15 cm circular platform in one of the four identical quadrants.
Cues were placed on each wall of the quadrant, including a colorful During the spatial reference memory task, the platform was hidden 1-2 cm below the surface of the water, and its location remained constant during all the training sessions (hidden days 1-5, HD1-5). The rat was placed near the edge of the pool with its head directed toward the wall of the pool (in one of the starting locations randomly) in each session. All the rats swam until they located and climbed onto the platform, and the latency to find the platform was recorded. If the rat did not find the platform within 120 seconds, then it was manually guided to the platform and allowed to remain on the platform for 15 seconds. In this case, a maximum latency of 120 seconds was recorded. Two parameters were measured: latency to reach the critical annulus (the virtual contour of the removed plat- 
| Tissue immunofluorescence and image analysis
The rats were decapitated at 12:00 pm on day 14 after the STZ or vehicle injection (n = 6-8). Under chloral hydrate (300 mg/kg, i.p.)
anesthesia, the rats were transcardially perfused with cold phosphate-buffered saline (PBS) followed by 4% paraformaldehyde in PBS (pH 7.4). The perfusion, cryoprotection, and frozen brain sections were prepared as described previously. The data from each group are expressed as mean ± SEM.
| Estimation of GABA and glutamate
The neurotransmitter analysis was conducted as described by Cao with slight modifications 14 . The rats were decapitated at 12:00 pm on day 14
after the STZ or vehicle injection (n = 6-8). After the rats were decapitated, the brains were quickly removed to a prechilled brain matrix with [pH 6.00 with H 3 PO 4 ]) and ECD detection (analytical cell: 5011A, E1 = −10 mV, E2 = +600 mV; guard cell: 5020, EGC = +650 mV). GABA and glutamate standards were purchased from Sigma-Aldrich.
| Microinjection in the parabrachial nucleus (PBN)
A Hamilton syringe that was connected to the 33 gauge injection cannula (Plastics One) was used for the microinjections. Drug or vehicle in a volume of 0.2 μL was delivered through the injection cannula that extended 1 mm beyond the guide cannula over a 2-minutes period. Drug or vehicle might be diffused to the lateral parabrachial nucleus (dorsal, external, and internal parts), medial parabrachial nucleus and superior cerebellar peduncle, and ventral spinocerebellar tract. To allow the drug to diffuse from the tip completely, the injection cannula was kept in place for an additional 3 minutes. A group of rats received microinjection of the GABA receptor antagonist bicuculline (50 or 100 pmol/side, dissolved in aCSF) or vehicle in the PBN (n = 8-11). Another group of rats received microinjection of the GABA (5 or 10 μmol/side, dissolved in aCSF) or vehicle in the PBN on day 14 after the STZ injection (n = 8-11). EEG and EMG recordings were performed for 24 hours, from 9:00 am, immediately after bicuculline or GABA intra-PBN application.
| Histological verification of microinjection sites
At the end of the experiments, 20 μm thick sections were to histologi- 
| Statistical analysis
The data were analyzed using SPSS 20.0 software (Chicago, IL, USA) and are expressed as mean ± SEM. The escape latency in the MWM during the training period was analyzed using two-way repeatedmeasures analysis of variance (ANOVA). Significant group differences were analyzed using Tukey's multiple comparison post hoc test when appropriate. The data from the probe day of the MWM, sleep-wake stage analysis, neurotransmitter detection, and immunohistochemistry were analyzed using one-way ANOVA followed by the Student-Newman-Keuls post hoc test. Values of P < 0.05 were considered statistically significant.
| RE SULTS
| Streptozotocin-injected rats exhibited learning and memory deficits
Similar to previous studies, 15, 16 the post hoc tests indicated no significant difference in navigation path length on the first day among groups during the acquisition phase of the test. On day 15 after the STZ injection, the rats exhibited deficits in spatial learning, reflected by a longer latency to find the hidden platform compared with the vehicle groups (significant main effect of treatment, P < 0.01, Figure 1A ). During the visible platform trials, all of the rats performed equally well (P > 0.05, Figure 1A ). No significant difference in swim speed was observed among the three groups (data not shown), suggesting that the learning impairment was not attributable to motor or visual deficits. During the subsequent probe trial, STZ-injected rats spent less time in the target quadrant than the vehicle group (significant main effect of treatment, P < 0.01, Figure 1B) , indicating that the rats in our model exhibited impairments in memory retention. No significant differences in learning and memory were observed between the control and vehicle groups.
| Streptozotocin-injected rats exhibited disruption of the sleep-wake cycle
Consistent with alterations of sleep architecture in AD patients, the analysis of EEG-based vigilance staging on day 14 after the STZ injection indicated that the rats spent more time awake and less time in NREM sleep and REM sleep, especially SWS, during the 24-hours day compared with vehicle-treated rats (P < 0.05 or <0.01, Figure 2B ).
The bouts of wakefulness significantly increased, and the duration of wakefulness significantly decreased in the STZ group (P < 0.01, Figure 2C ). The injection of STZ significantly prolonged sleep latency (P < 0.01) and REM sleep latency (P < 0.01, Figure 2E ,F).
A previous study showed that disruption of the sleep-wake cycle that is induced by STZ was dramatic during the light period. 16 The increase in light-phase wakefulness among STZ-injected rats emerged at the expense of reductions of REM sleep and NREM sleep. However, the data that were obtained during the dark period revealed no significant differences in wakefulness, NREM sleep, and REM sleep between vehicle and STZ groups. 16 In this study, the distribution of total sleep was further assessed in 1-hour bins.
The time-course of hourly sleep-wake stage analysis showed that the STZ injection significantly decreased sleep time compared with the vehicle group in every 1-hour period during the light phase from 9:00 am to 9:00 pm. However, hourly sleep time was unaffected by the STZ during the dark phase, which is consistent with the previous study. 16 No significant differences in sleep parameters were observed between the control and vehicle groups.
| Decreases in REM and NREM sleep in STZ-injected rats were associated with the dysregulation of neuronal activity in sleep/wake regulating brainstem regions
Neuronal activity was evaluated in several regions that regulated sleep-wake states to study the possible mechanism of the wake-promoting effect that was observed in STZ-injected rats. The density of TH+ (noradrenergic) neurons in the LC and TrpOH+ (serotonergic) neurons in the DRN significantly decreased in STZ-injected rats (P < 0.01, Figure 3A ,B,E,F). We also found that STZ-injected rats expressed fewer dual c-Fos+ and TH+ neurons in the LC and dual c-Fos+ and TrpOH+ neurons in the DRN (P < 0.01, Figure 3A ,B,E,F).
Interestingly, no significant difference was found in the density of No significant differences in neuronal activity or neurotransmitter levels were observed between the control and vehicle groups.
| Intra-PBN bicuculline-induced sleep phenotype paralleled sleep disturbances in STZinjected rats
We next examined whether dysregulation of the GABAergic system in the PBN is related to sleep disturbances in rats. An additional group of rats was surgically implanted with cannulas and and decreased the percentage of SWS relative to total sleep (SWS%, P < 0.05, Figure 5C ). The administration of bicuculline (100 pmol/ side) significantly prolonged sleep latency and REM sleep latency (P < 0.05, Figure 5D ,E). The microinjection of bicuculline (100 pmol/ 
| D ISCUSS I ON
Clinically, learning and memory deficits are early symptoms and hallmarks of AD. 19, 20 Experimental observations indicate that pathological and behavioral changes in the rat model of AD that is induced by an i.c.v. injection of STZ recapitulate the symptoms and pathogenesis of sAD patients. 21 In the present study, memory performance in STZ-injected rats was evaluated using behavioral assays of learning and memory to confirm that our rats were a valid model of sAD.
We found that STZ-injected rats spent more time awake and less 30 The genetically driven disruption of glutamate transmission by PBN neurons results in a large reduction in total wake time and a slowing of waking EEG. 27 The present study found that Altogether, the present results suggest that inactivation of the GABAergic system in the PBN may be associated with the development of sleep disorders in STZ-injected rats. However, activation of the GABAergic system in the PBN did not reverse the decrease in REM sleep, suggesting that the mechanisms of STZ-induced sleep disorders may not exclusively involve the GABAergic system in the PBN.
Projections from the PBN that are relayed by the basal forebrain to the cerebral cortex may play a critical role in behavioral or electrocortical arousal. 28 In STZ-injected rats, the preoptic area, hypothalamus, lateral hypothalamus, and thalamus may also mediate the PBN's control of wakefulness because these forebrain structures are also densely innervated by the PBN and provide direct innervations of the cortex. 17 However, the neurocircuitry through which PBN GABAergic neurons drive arousal in STZ-injected rats remains unclear, and the role of these respective PBN afferent pathways in arousal needs further investigation.
Alzheimer's disease patients often exhibit disruptions of circadian rhythm and mistimed sleep, which can cause great morbidity and is a major cause of institutionalization. 22 Although these sleep and circadian abnormalities were once mistaken as consequences of the disease process, accumulating evidence suggests that circadian disturbances likely occur early in the disease process and may contribute to the pathogenesis of AD. 31 The association between disruptions of sleep and circadian rhythm and the progression of AD presents an opportunity to target preclinical symptoms of AD to prevent the further progression of neurodegeneration. 
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